Longboard Pharmaceuticals, Inc. (LBPH) shares are surging more than 177 percent on Tuesday morning trade after the company announced positive results from phase 1b/2a PACIFIC clinical trial of Bexicaserin for developmental and epileptic encephalopathies.
Longboard Pharmaceuticals Inc.’s positive – and then some – phase Ib/IIa top-line data with 5-HT2C receptor superagonist bexicaserin (LP-352) in developmental and epileptic encephalopathies (DEEs) sparked Wall Street speculation about competitive odds as well as the shape of the firm’s upcoming phase III effort.
Longboard Pharmaceuticals, Inc. (LBPH) shares are surging more than 177 percent on Tuesday morning trade after the company announced positive results from phase 1b/2a PACIFIC clinical trial of Bexicaserin for developmental and epileptic encephalopathies.
/PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nine company-sponsored presentations, including five late-breaking abstracts, will.